Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Pear Therapeutics (PEAR) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Pear Therapeutics (PEAR) lobbying for?
Summary of the lobbying data:
– Lobbying firms hired: Bluebird Strategies, Llp, K&L Gates
– General issues they lobbied on: Budget/Appropriations, Medicare/Medicaid, Health Issues
– Specific issues they lobbied on:
– Mental health prescription digital therapeutics coverage
– Medicare/Medicaid coverage report language
– Access to Prescription Digital Therapeutics Act of 2022; Federal policy related to prescription digital therapeutics
– Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics
– H.R.7051, S.3791, Access to Prescription Digital Therapeutics Act of 2022; Federal policy related to prescription digital therapeutics
– S.5238, Medicaid and CHIP Access to Prescription Digital Therapeutics Act; Federal policy related to prescription digital therapeutics
– Federal policy related to prescription digital therapeutics (no specific legislation)
– Government agencies they lobbied: Senate, Department of Health & Human Services (HHS), House of Representatives
One could infer that Pear Therapeutics is lobbying on these issues because they are involved in the development and marketing of prescription digital therapeutics, which is a new and emerging field. They are likely advocating for the establishment of Medicare and Medicaid coverage for these therapies, as well as for federal policies that support their development and adoption. Additionally, by lobbying on mental health prescription digital therapeutics coverage, they may be seeking to improve access to their own products, as well as those of their competitors.
